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Background: Physicians depend on reliable information on the local epidemiology of infection and antibiotic
resistance rates to guide empiric treatment in critically ill patients. As these data are scarce for Central Africa, we
performed a retrospective analysis of microbiological findings from a secondary care hospital in Gabon.
Methods: Microbiological reports from 2009 to 2012 were used to assess the non-susceptibility rates of the three
most common isolates from six major types of infections (bloodstream, ear-eye-nose-throat, surgical site, skin and
soft tissue, urinary tract and wound infection).
Results: A high diversity of pathogens was found, but Staphylococcus aureus was predominant in the majority of
infections. Overall, the three most prevalent pathogens in children were S. aureus (33.7%), Streptococcus pyogenes (8.1%)
and Escherichia coli (4.5%) and in adults S. aureus (23.5%), E. coli (15.1%) and Klebsiella pneumoniae (7.4%). In total, 5.8%
(n = 19) of all S. aureus isolates were methicillin resistant. The proportion of extended-spectrum beta-lactamase (ESBL)
producing Enterobacteriaceae was 15.4% (n = 78), 49.4% of all K. pneumoniae were ESBL-producer (n = 42).
Conclusion: The high diversity of potential pathogens and high resistance rates in Gram-negative bacteria challenge a
rational empiric use of antibiotics. Countrywide continuous sentinel surveillance is therefore urgently needed.
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The knowledge of the infection epidemiology and the anti-
biotic resistance patterns is essential to guide optimal
empiric treatment in critically ill patients. Antibacterial
susceptibility patterns and bacterial spectra vary geograph-
ically, highlighting the importance of local surveillance
data. In industrialized countries, these data are available at
regional, national and international levels; for instance as
provided by the European Antimicrobial Resistance Sur-
veillance System (EARSS) database [1]. However, current
surveillance data are scarce in Africa [2,3]. The lack of sur-
veillance is alarming as some reports might only show the
“tip of the iceberg” such as a 15.5% ciprofloxacin resistance* Correspondence: frieder.schaumburg@ukmuenster.de
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reproduction in any medium, provided the orin Salmonella enterica Typhi reported from DR Congo
[4], 18% penicillin non-susceptibility in Streptococcus
pneumoniae in remote regions in Gabon [5] and up to 31%
colonization rates with extended-spectrum beta-lactamase
(ESBL) producing Enterobacteriaceae on hospital admission
in Niger [6]. At the moment, these emerging resistances in
Africa are a challenge but might become devastating con-
sidering the limited access to second line drugs (e. g. vanco-
mycin, carbapenems) in these regions. To provide data for
the rational use of antibiotics and tools for target-oriented
infection control-measures, we report the antimicrobial re-
sistance rates and bacterial spectra of infections in a sec-
ondary care hospital in semi-urban Gabon.Methods
Sample collection
This retrospective analysis of antimicrobial resistance
in Gabon, Central Africa consists of data from thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic characteristics of the study
population
Children Adults
Patients, n (%) 2009 60 (9.4) 91 (23.0)
2010 132 (20.8) 79 (20.0)
2011 235 (37.0) 111 (28.1)
2012 209 (32.9) 114 (28.9)
Total 636 (100) 395 (100)
Sex, n (%) Female 289 (46.5) 263 (70.5)
Mean age in years (range) 3.6 (0–18) 37.8 (18.3-89.7)
No of different species
per patient (± SD)
1.1 (0.48) 1.3 (0.68)
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(HAS) in Lambaréné. All microbiological reports on bac-
terial pathogens between January 2009 and September
2012 were included. Ethical approval was not obtained as
retrospective studies such as our study do not require eth-
ical approval in Gabon. No inclusion or exclusion criteria
were applied. The decision to take samples for microbio-
logical culture and the selection of samples was made by
the physicians. We used commercial blood culture bottles
(BacT/ALERT, bioMérieux, Marcy l'Etoile, France) to as-
sess bacteremia and sterile cotton (Transswab, MWE,
Corsham, England) for superficial infections, urine sam-
ples were collected in sterile single-use pots for microbio-
logical culture.
Microbiological analyses
Standard culture based methods were used for species
identification (API Test stripes, bioMérieux, France and
BBL Enterotubes or BBL Oxi/Ferm Tube, BD, Germany).
Antimicrobial susceptibility testing was performed using
the disk-diffusion method and was reported according to
Clinical Laboratory Standards Institute (CLSI) guidelines
[7]. Inducible clindamycin resistance was not routinely
tested in our laboratory and is therefore not reported. We
report the non-susceptibility rates, which include both
intermediate and resistant isolates. The production of
extended-spectrum beta-lactamase was confirmed in allTable 2 Distribution of isolates from various infections
Children, n (%)
Bloodstream infection 126 (17.0)
Ear, eye, nose, throat infection 167 (22.6)
Surgical site infection 35 (4.7)
Skin and soft tissue infection 155 (21.0)
Urinary tract infection 70 (9.5)
Wound infection 76 (10.3)
Others 111 (15.0)
Total 740 (100)ceftriaxone resistant Enterobacteriaceae using the double-
disks method according to the manufacturer’s instruction
(Mast discs, Mast diagnostics, Bootle, UK). This test applies
discs of three different beta-lactam antibiotics (ceftazidim
30 μg, cefotaxime 30 μg, cefpodoxime 10 μg) with and
without clavulanic acid. Methicillin-resistance was con-
firmed for all cefoxitin-resistant Staphylococcus aureus
using a PBP2a-agglutination test (PBP2’ Test Kit, Oxoid,
Japan). As part of a clinical trial requirement, the microbiol-
ogy laboratory at the HAS successfully participates in regu-
lar external quality assurance (EQA) programs addressing
species identification and susceptibility testing. The EQA is
part of the WHO/NICD Proficiency Testing Scheme, and
is organized by the Contract Laboratory Services (CLS),
Johannesburg, South Africa.
Statistics
In our analysis, children (≤ 18 years old) and adults
(> 18 year old) were assessed separately. Types of infection
were categorized as “bloodstream infection” (sepsis, bac-
teremia), “ear, eye, nose, throat infection” (pharyngitis,
upper-respiratory tract infection, conjunctivitis, otitis),
“surgical site infection”, “skin and soft tissue infection”
(pyoderma, impetigo, pyomyositis, abscesses, ulcer), “urin-
ary tract infection” and “wound infection” [8]. All data
were entered in one excel spreadsheet and analyzed using
‘R’, version 2.13.1 (http://www.cran.r-project.org) and the
package “epicalc”. Categorical variables were compared
using Chi-square test. The odds ratio (OR) and the 95%
confidence interval (95% CI) were calculated to assess the
association. The significance level was p < 0.05.
Results
Study population
The proportion of children was higher compared to adults
(Table 1). Similarly, the isolates from different groups of
infections were not equally distributed among children
and adults (Table 2). In total, 34.1% (n = 434) of all cases
received a pre-sampling antibiotic treatment. Of these, the
majority received ampicillin/amoxicillin (37.6%, n = 163),
cloxacillin (16.4%, n = 71), ceftriaxone (15.0%, n = 65),Adults, n (%) OR (95% CI) p-value
81 (15.3) 1.1 (0.8-1.6) 0.4
6 (1.1) 25.5 (11.3-70.9) <0.0005
106 (20.0) 0.2 (0.1-0.3) <0.0005
37 (7.0) 3.5 (2.4-5.3) <0.0005
94 (17.7) 0.5 (0.3-0.7) <0.0005
68 (12.8) 0.8 (0.5-1.1) 0.2
139 (26.2) 0.5 (0.4-0.7) <0.0005
531 (100) - -
Table 3 The three most frequent pathogens from major





Bloodstream infection Klebsiella pneumoniae 21 (16.7) -
Staphylococcus aureus 15 (11.9) 15 (18.5)




Others 76 (59.5) 44 (54.3)
Ear, eye, nose,
throat infection
Staphylococcus aureus 37 (22.2) 1 (16.7)
Pseudomonas
aeruginosa
15 (9.0) 1 (16.7)
Proteus mirabilis 14 (8.4) 1 (16.7)
Others 101 (60.5) 3 (50.0)
Surgical site infection Staphylococcus aureus 9 (25.7) 33 (32.0)
Escherichia coli - 15 (14.2)
Enterococcus faecalis 6 (17.1) -
Proteus mirabilis 4 (11.4) 7 (6.6)
Others 16 (45.7) 51 (48.1)
Skin and soft
tissue infection
Staphylococcus aureus 116 (74.8) 28 (75.7)
Streptococcus pyogenes 31 (20.0) 1 (2.7)
Klebsiella pneumoniae 2 (1.3) 2 (5.4)
Others 6 (3.9) 6 (16.2)
Urinary tract infection Escherichia coli 28 (40.0) 36 (38.3)
Proteus mirabilis 9 (12.9) 4 (4.3)
Klebsiella pneumoniae 4 (5.7) 19 (20.2)
Others 29 (41.4) 35 (37.2)
Wound infection Staphylococcus aureus 35 (46.1) 15 (22.1)




Escherichia coli - 8 (11.8)
Proteus mirabilis - 8 (11.8)
Others 14 (18.4) 37 (54.4)
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or cotrimoxazole (3.0%, n = 13).
Bacterial spectrum
In total, 1271 isolates were included in this study compris-
ing isolates from 2009 (n = 234), 2010 (n = 273), 2011 (n =
397) and 2012 (n = 367). Noteworthy, adults and children
frequently share the three most common bacterial patho-
gens but the distribution of these pathogens was different
in both groups. For instance, the most frequent isolate
from blood cultures in children was Klebsiella pneumoniae
(16.7%, n = 21) followed by S. aureus (11.9%, n = 15) and
Salmonella enterica (11.1%, n = 14). Similarly, S. aureus
was most frequently found in blood cultures from adults
(18.5%, n = 15) followed by S. enterica (14.8%, n = 12) and
Streptococcus pneumoniae (12.3%, n = 10, Table 3). The
spectrum of bacterial pathogens was highly diverse for the
majority of infections. For instance, the three most frequent
species comprised only one half of all pathogens isolated
from blood cultures, ear, eye, nose and throat infection (S.
aureus, Pseudomonas aeruginosa, Proteus mirabilis) or sur-
gical site infections (S. aureus, P. mirabilis, Escherichia coli
and Enterococcus faecalis, respectively, Table 3). The bacter-
ial spectrum was less diverse in skin and soft tissue infec-
tions as S. aureus dominated in children (74.8%, n = 116)
and adults (75.7%, n = 28, Table 2). Urinary tract infections
were dominated by E. coli, K. pneumoniae and P. mirabilis
both in children and adults. Wound infections in children
were frequently caused by S. aureus (46.1%, n = 35) and
Streptococcus pyogenes (26.3%, n = 20, Table 2).
Antibiotic non-susceptibility
The overall proportion of methicillin resistant S. aureus
(MRSA) was 5.8% (n = 19) and fluctuated during the
studied period between 3.9% (n = 2, 2009), 10.9% (n = 7,
2010), 5.2% (n = 5, 2011) and 3.3% (n = 4, 2012). The
non-susceptibility rates (methicillin, erythromycin and
clindamycin) of S. aureus from bloodstream infection
were lower than in non-invasive isolates (Tables 4 and 5).
The non-susceptibility of streptococci against penicillin
was 8.6% (non-invasive S. pyogenes), 6.7% (non-invasive
S. pneumoniae, Table 5) and 25% (S. pneumoniae from
bloodstream infection, Table 4). Noteworthy, the two
major Gram-negative bacteria K. pneumoniae and E. coli
were frequently non-susceptible to combinations of
aminopenicillins with beta-lactamase inhibitors. The
overall non-susceptibility against third generation cepha-
losporins in K. pneumoniae was 50.6% (n = 43), ESBL-
production was confirmed in all but one cases (49.4%,
n = 42). The proportion of ESBL-producers among all
Enterobacteriaceae throughout the observation period
was 15.0% (n = 15, 2009), 18.9% (n = 27, 2010), 13.5%
(n = 20, 2011) and 13.2% (n = 15, 2012). Despite its wide
use in the hospital and other health care facilities in theregion, the non-susceptibility to ciprofloxacin was diverse
and ranged from 0% (Salmonella enterica) to 97.1% (K.
pneumoniae, Table 4). The non-susceptibility rates of P.
aeruginosa were very low, non-susceptibility to ciproflox-
acin was reported in only one isolate (2.6%, Table 3).
Discussion
In this retrospective study we analyzed the infection epi-
demiology and the antibiotic resistance patterns of bacterial
pathogens isolated in a secondary care hospital in Gabon,
Central Africa. Main findings are the predominance of S.
aureus in major infections (ear, eye, nose and throat
Table 4 Non-susceptibility rates of the most prevalent bacterial pathogens from bloodstream infections in Gabon
Pathogen (n) Antimicrobial non-susceptibility (%)
PEN/AMPa COX AMP + BLI CRO GEN CIP CHL CLI ERY SXT TCY
S. aureus (30) 89.7 0 0 0 0 0 0 0 10 7.8 66.7
S. pyogenes (3) 0 - - 0 - - ND 0 0 0 -
S. pneumoniae (15) 25 - - 25 - - 33.3 14.3 13.3 71.4 ND
K. pneumoniae (29) 100 - 92.6 74.1 75 37.9 100 - - 96.3 ND
P. agglomerans (11) 90.9 - 81.8 80 45.4 18.2 50 - - 80 ND
E. coli (16) 81.2 - 62.5 0 6.3 12.5 66.7 - - 81.2 ND
S. enterica (26) 3.9 - 3.9 3.9 0 0 11.1 - - 4 0
Note: Abbrevations are penicillin/ampicillin (PEN/AMP), cefoxitin (COX), ampicillin plus betalactamase-inhibitor (AMP + BLI), ceftriaxone (CRO), gentamicin (GEN),
ciprofloxacin (CIP), chloramphenicol (CHL), clindamycin (CLI), erythromycin (ERY), cotrimoxazole (SXT), tetracycline (TCY), not done (ND). Non-susceptible isolates
are shown as the percentage of tested isolates. Data from P. aeruginosa and P. mirabilis were not reported due to small sample size (n = 2).
aShown is the non-susceptibility of Gram-positives to penicillin and the non-susceptibility of Gram-negatives to ampicillin.
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infections) and a high prevalence of ESBL-producing
Enterobacteriaceae, in particular K. pneumoniae.
The major cause of bloodstream infections in chil-
dren was K. pneumoniae which is in contrast to one re-
port from Ghana and a large meta-analysis from Africa
where Salmonella spp. was most frequently found
[9,10]. An empirical treatment with cotrimoxazole and
sometimes even ciprofloxacin before taking blood cul-
tures in our hospital might explain this difference as
non-susceptibility rates of S. enterica were low against
cotrimoxazole (4–12.5%%) and ciprofloxacin (0%) in
our setting (Tables 4 and 5).
The predominance of S. aureus in bloodstream infec-
tions in adults (18.5%, Table 3) is in contrast to a large
meta-analysis of community-acquired bloodstream in-
fections as S. aureus was only reported in 5.4% of casesTable 5 Non-susceptibility rates of the most prevalent non-in
Pathogen (n) Antimic
PEN/AMPa COX AMP + BLI CRO
S. aureus (312) 94.2 8.33 8.33 8.33
S. pyogenes (69) 8.6 - - 0
S. pneumoniae (19) 6.7 - - ND
E. faecalis (19) 0 - - -
K. pneumoniae (56) 100 - 51.9 38.9
P. agglomerans (6) 83.3 - 75.5 ND
P. aeruginosa (39) - - 0b 0c
P. mirabilis (52) 34.6 - 17.3 2.1
E. coli (114) 80.4 - 60.3 16.4
S. enterica (9) 22.2 - ND 0
Note: Abbrevations are penicillin/ampicillin (PEN/AMP), cefoxitin (COX), ampicillin p
ciprofloxacin (CIP), chloramphenicol (CHL), clindamycin (CLI), erythromycin (ERY), co
are shown as the percentage of tested isolates.
aShown is the non-susceptibility of Gram-positives to penicillin and the non-suscep
bNon-susceptibility to piperacillin/tazobactam.
cNon-susceptibility to ceftazidim.
dNon-susceptibility to amikacin.[10]. This high proportion in our study is unclear and
could be due to the frequent pre-sampling empirical treat-
ment with ampicillin/amoxicillin (37.6% of all patients re-
ceived ampicillin/amoxicillin), against which S. aureus is
highly resistant in Gabon (94.2% and 89.7%, respectively,
Table 3) [11]. However, one prospective study from
Tanzania also reports S. aureus as the main pathogen of
bloodstream infection in newborns between 7–28 days of
age [12].
We found a non-susceptibility to penicillin in S. pyogenes
of 8.6% (Table 5) which has not yet been reported in sub-
Saharan Africa. In general, a universal susceptibility to
penicillin is assumed [13]. However, determination of the
minimal inhibitory concentration using the microdilution
methods was not available to confirm penicillin resistance
in S. pyogenes.vasive bacterial pathogens from Gabon
robial non-susceptibility (%)
GEN CIP CHL CLI ERY SXT TCY
2.3 9.4 0.9 2.5 17.0 8.3 37.5
- - 9.1 7.8 7.9 56.0 -
- - 14.3 10.5 11.1 82.4 ND
- 81.3 - - - - -
38.2 21.4 55.6 - - 60 ND
0 0 ND - - 0 ND
0d 2.6 - - - - -
13.5 1.9 44.4 - - 48.9 ND
14.7 24.1 35.5 - - 88.1 ND
0 0 0 - - 12.5 0
lus betalactamase-inhibitor (AMP + BLI), ceftriaxone (CRO), gentamicin (GEN),
trimoxazole (SXT), tetracycline (TCY), not done (ND). Non-susceptible isolates
tibility of Gram-negatives and E. faecalis to ampicillin.
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stream infections, ear, eye, nose, throat and surgical site
infections challenges an empirical antibiotic therapy. We
strongly recommend species identification and suscepti-
bility tests in these cases. Our data can be used to guide
empiric therapy for skin and soft tissue as well as wound
infections which were predominantly caused by S. aur-
eus and S. pyogenes. Based on our survey, the suscepti-
bility rate of all isolates from wound infections is 76.7%
(clindamycin) and 75.1% (cephalosporin, cloxacillin) in
children and 76.5% (clindamycin) and 74.1% (cephalo-
sporin, cloxacillin) in skin and soft tissue infections in
adults. Therefore the coverage rate in skin and soft tissue
infections in children would be 91.6% (clindamycin) and
90.5% (cephalosporin, cloxacillin). If microbiological diag-
nostics are not available, we recommend clindamycin or a
combination of amoxicillin/clavulanate or cefuroxime or
cloxacillin in mild to moderate wound or skin and soft tis-
sue infections [14]. Intravenous antibiotic agents should
be considered in severe infections. The prevalence of the
S. aureus protein toxin Panton-Valentine leukocidin (PVL)
is high in Gabon (44.7-55.9%) and can be associated with
abscesses [15,16]. We are therefore in favor of clindamycin
as it reduces the production in PVL even in sub-inhibitory
concentrations in vitro [17].
The MRSA rate of 5.8% is lower compared to a meta-
analysis of S. aureus isolates from Central Africa (27.7%)
and another study on clinical S. aureus isolates from this
region (11.1%) or in a study on neonatal bloodstream in-
fection on Tanzania (28%) [3,12,15]. The high rate of
ESBL-producing K. pneumoniae (49.4%) is alarming as K.
pneumoniae was frequently isolated from bloodstream in-
fection, skin and soft tissue infection or urinary tract infec-
tion (Table 3). Data on the prevalence of ESBL-producers
from clinical samples are scarce in Central Africa. One re-
port from 2005 shows a prevalence of ESBL-producing
Enterobacteriaceae of 12% in Cameroon with a predomin-
ance of K. pneumoniae (18.8%) [18]. Several reports from
Tanzania show a higher proportion of ESBL-producing
Enterobacteriacea (29.2-50%) [19,20]. However, there is
evidence for an increasing prevalence of ESBL-producers,
considering carrier rates of 33.6% in children admitted to
the HAS in Lambaréné, Gabon [21]. This observation has
already direct impact in the choice of drugs.
Our report on bacterial spectra of major infections
and antimicrobial non-susceptibility patterns enables a
more rational use of antibiotics. This is of outmost im-
portance, not only for patients in Gabon but also for
travelers returning from the tropics which have ac-
quired infections in the visited country [22]. Our study
provides the basis for future prospective studies for in-
stance on invasive infections and clearly points out the
need for a more rational use of antibiotic agents paired
with improved education of health care workers on theuse of anti-infective drugs as part of antibiotic steward-
ship programs.
Although the data we present are very valuable in a set-
ting where information on antimicrobial resistance is se-
verely limited, some limitations need to be addressed. First,
based on the reports of microbiological findings we were
not able to distinguish community from hospital acquired
infections. The source of infection is therefore blurred.
Second, some samples have also been taken after starting
an antibiotic treatment, which may lead to selection and
over-representation of resistant isolates. Third, we were
unable to provide further epidemiological data (e. g. place
of residence, onset of disease). Fourth, the collection of
samples for microbiological culture was not systematic but
based on the physician’s judgment which might be a sam-
pling bias.
Conclusion
Our analysis provides important data of bacterial spectra
and antimicrobial resistance in a semi-urban setting in
Africa. S. aureus is the predominant pathogen and the
high proportion of ESBL-producing K. pneumoniae is
alarming. The high diversity of pathogens challenges an
empirical use of antibiotics. A countrywide continuous
sentinel surveillance is therefore urgently needed.Abbreviations
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